158 related articles for article (PubMed ID: 38415533)
1. Investigation of Fibroblast Growth Factor Peptide Antagonist on Mouse Model Breast Tumor through ERK/MAPK and PI3K/AKT Signaling Pathways.
Ghadirian S; Tabibzadeh A; Rezvani H; Jafarzadeh M
Asian Pac J Cancer Prev; 2024 Feb; 25(2):473-483. PubMed ID: 38415533
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
3. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
4. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice.
Feng XY; Chen BC; Li JC; Li JM; Li HM; Chen XQ; Liu D; Li RT
Phytomedicine; 2021 Dec; 93():153779. PubMed ID: 34638030
[TBL] [Abstract][Full Text] [Related]
5. Jujuboside B Reverse CUMS-Promoted Tumor Progression via Blocking PI3K/Akt and MAPK/ERK and Dephosphorylating CREB Signaling.
Yang Z; Cai W; Chen Y; Guo Z; Xiao Z; Zhou T; Cheng Y; Xu F
J Immunol Res; 2022; 2022():5211368. PubMed ID: 36254198
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
7. Calotropis Procera Induced Caspase-Dependent Apoptosis and Impaired Akt/mTOR Signaling in 4T1 Breast Cancer Cells.
Rabelo ACS; Miglino MA; Arbizu S; Carreira ACO; Filho AJC; Carneiro FJC; Layosa MAA; Noratto G
Anticancer Agents Med Chem; 2022; 22(18):3136-3147. PubMed ID: 35676853
[TBL] [Abstract][Full Text] [Related]
8. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
9. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
10. EGF/EGFR Promotes Salivary Adenoid Cystic Carcinoma Cell Malignant Neural Invasion
Ren Y; Hong Y; He W; Liu Y; Chen W; Wen S; Sun M
Curr Cancer Drug Targets; 2022; 22(7):603-616. PubMed ID: 35410600
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
12. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways.
Lu H; Jiang T; Ren K; Li ZL; Ren J; Wu G; Han X
Cell Physiol Biochem; 2018; 49(1):217-225. PubMed ID: 30138923
[TBL] [Abstract][Full Text] [Related]
13. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways.
Wang N; Li Y; Wei J; Pu J; Liu R; Yang Q; Guan H; Shi B; Hou P; Ji M
Thyroid; 2019 Mar; 29(3):378-394. PubMed ID: 30543152
[TBL] [Abstract][Full Text] [Related]
14. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
15. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways.
Li CY; Wang Q; Wang XM; Li GX; Shen S; Wei XL
Eur J Pharmacol; 2019 Dec; 864():172719. PubMed ID: 31586634
[TBL] [Abstract][Full Text] [Related]
16. Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.
Zhang L; Huo X; Liao Y; Yang F; Gao L; Cao L
Sci Rep; 2017 May; 7(1):1669. PubMed ID: 28490807
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells.
Lau MT; So WK; Leung PC
PLoS One; 2013; 8(3):e59083. PubMed ID: 23554977
[TBL] [Abstract][Full Text] [Related]
18. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
19.
Wang C; He Q; Yin Y; Wu Y; Li X
Front Cell Infect Microbiol; 2021; 11():734750. PubMed ID: 34858869
[TBL] [Abstract][Full Text] [Related]
20. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms.
Su X; Shen Z; Yang Q; Sui F; Pu J; Ma J; Ma S; Yao D; Ji M; Hou P
Theranostics; 2019; 9(15):4461-4473. PubMed ID: 31285773
[No Abstract] [Full Text] [Related]
[Next] [New Search]
